Director at Outlook Therapeutics (OTLK) buys 400K common shares
Rhea-AI Filing Summary
Outlook Therapeutics director Kurt J. Hilzinger increased his personal stake by buying 400,000 shares of Common Stock in an open-market purchase. The shares were acquired at an average price of $0.4413 per share. Following this transaction, he directly owns 423,655 shares of Outlook Therapeutics common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 400,000 shares
Net Buy
1 txn
Insider
HILZINGER KURT J
Role
Director
Bought
400,000 shs ($177K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 400,000 | $0.4413 | $177K |
Holdings After Transaction:
Common Stock — 423,655 shares (Direct)
Key Figures
Shares purchased: 400,000 shares
Purchase price: $0.4413 per share
Shares owned after transaction: 423,655 shares
+2 more
5 metrics
Shares purchased
400,000 shares
Open-market purchase of Common Stock
Purchase price
$0.4413 per share
Average transaction price on purchase date
Shares owned after transaction
423,655 shares
Direct holdings following the reported trade
Net buy shares
400,000 shares
Net buy direction in transaction summary
Buy transactions count
1 transaction
Number of buy entries in this Form 4
Key Terms
open-market purchase, Common Stock, non-derivative, net-buy
4 terms
open-market purchase financial
"transaction_action: open-market purchase"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Common Stock financial
"security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
non-derivative financial
"transaction_type: non-derivative"
net-buy financial
"netBuySellDirection: net-buy"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Outlook Therapeutics (OTLK) disclose?
Outlook Therapeutics disclosed that director Kurt J. Hilzinger completed an open-market purchase of 400,000 shares of Common Stock. The transaction reflects a direct acquisition of shares rather than an option exercise or derivative conversion, indicating an increase in his equity position.
What are Kurt J. Hilzinger’s Outlook Therapeutics holdings after this Form 4 trade?
After the reported purchase, Kurt J. Hilzinger directly holds 423,655 shares of Outlook Therapeutics Common Stock. The Form 4 indicates these shares are held with direct ownership, meaning they are attributed personally rather than through an intermediary entity or trust.
Was the Outlook Therapeutics Form 4 transaction a buy or a sell?
The Form 4 transaction was a buy. It is coded as an open-market purchase, with 400,000 Common Stock shares acquired. The transaction direction is explicitly classified as a net buy, with no reported sales or derivative exercises in this filing.
Does this Outlook Therapeutics Form 4 involve derivatives or options?
No, this Form 4 reports only a non-derivative transaction in Common Stock. The derivativeSummary is empty, and the filing shows no option exercises, conversions, or other derivative-related trades, focusing solely on the open-market share purchase by the director.